Introduction: Reliance on administrative data sources and a cohort with restricted age range (Medicare 65 y and above) may limit conclusions drawn from public reporting of 30-day mortality rates in 3 diagnoses [acute myocardial infarction (AMI), congestive heart failure (CHF), pneumonia (PNA)] from Center for Medicaid and Medicare Services.
Methods: We categorized patients with diagnostic codes for AMI, CHF, and PNA admitted to 138 Veterans Administration hospitals (2006-2009) into 2 groups (less than 65 y or ALL), then applied 3 different models that predicted 30-day mortality [Center for Medicaid and Medicare Services administrative (ADM), ADM+laboratory data (PLUS), and clinical (CLIN)] to each age/diagnosis group. C statistic (CSTAT) and Hosmer Lemeshow Goodness of Fit measured discrimination and calibration. Pearson correlation coefficient (r) compared relationship between the hospitals' risk-standardized mortality rates (RSMRs) calculated with different models. Hospitals were rated as significantly different (SD) when confidence intervals (bootstrapping) omitted National RSMR.
Results: The ≥ 65-year models included 57%-67% of all patients (78%-82% deaths). The PLUS models improved discrimination and calibration across diagnoses and age groups (CSTAT-CHF/65 y and above: 0.67 vs. 0. 773 vs. 0.761; ADM/PLUS/CLIN; Hosmer Lemeshow Goodness of Fit significant 4/6 ADM vs. 2/6 PLUS). Correlation of RSMR was good between ADM and PLUS (r-AMI 0.859; CHF 0.821; PNA 0.750), and 65 years and above and ALL (r>0.90). SD ratings changed in 1%-12% of hospitals (greatest change in PNA).
Conclusions: Performance measurement systems should include laboratory data, which improve model performance. Changes in SD ratings suggest caution in using a single metric to label hospital performance.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/MLR.0b013e318245a5f2 | DOI Listing |
Med Care
December 2024
Department of Health Care Policy, Harvard Medical School, Boston, MA.
Objective: To quantify quality of care following an admission to a nursing home with low or high antipsychotic drug use.
Background: Misuse of antipsychotics in U.S.
Med Care
December 2024
Department of Health Services Administration, School of Health Professions University of Alabama at Birmingham, Birmingham, AL.
Objective: To assess the association of agency nursing staff utilization with nursing home (NH) quality.
Background: Nursing staff are the primary caregivers in NHs, where high-quality care is contingent upon their adequacy and expertise. Long-standing staffing challenges, exacerbated by the COVID-19 pandemic, have led NHs to rely on agency/contract labor to alleviate staffing shortages.
Objective: The objective of this study was to compare 2 approaches for representing self-reported race-and-ethnicity, additive modeling (AM), in which every race or ethnicity a person endorses counts toward measurement of that category, and a commonly used mutually exclusive categorization (MEC) approach. The benchmark was a gold-standard, but often impractical approach that analyzes all combinations of race-and-ethnicity as distinct groups.
Methods: Data came from 313,739 respondents to the 2021 Medicare Consumer Assessment of Healthcare Providers and Systems (CAHPS) surveys who self-reported race-and-ethnicity.
Health Serv Res
December 2024
Department of Economics, College of Business, University of Louisville, Louisville, Kentucky, USA.
Objective: To examine the impact of medical and recreational cannabis laws on inpatient visits for asthma and by payer-type.
Study Setting And Design: Quasi-experimental difference-in-differences regression analysis was conducted while accounting for variations in cannabis laws implementation timing by states. Inpatient visits for asthma in states with a given type of cannabis law were compared with those in states that did not implement the specific law.
Pharmacoeconomics
December 2024
Schumpeter School of Business and Economics, University of Wuppertal, Wuppertal, Germany.
Objectives: For US Medicare and Medicaid, single drug prices do not reflect the value of supplemental indications. Value-based indication-specific and weighted-average pricing has been suggested for drugs with multiple indications. Under indication-specific pricing, a distinct price is assigned to the differential value a drug offers in each indication.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!